Table 1 |
||
|
Prevalence of the antibody response in 200 individuals with patent Plasmodium vivax malaria |
||
| Number of positive sera (%) |
||
|
|
||
| Recombinant protein |
IgG |
IgM |
|
|
||
| VIR-A4 |
22 (11.0) |
36 (18.1) |
| VIR-B10 |
22 (11.0) |
18 (9.0) |
| VIR-C1 |
23 (11.5) |
12 (6.0) |
| VIR-C2 |
35 (17.5) |
22 (11.0) |
| VIR-C16 |
4 (2.0) |
30 (15.1) |
| VIR-E5 |
20 (10.0) |
26 (13.1) |
| VIR-E8 |
5 (2.5) |
30 (15.1) |
| AMA-1 |
114 (57.0) |
ND |
| MSP119 |
181 (90.5) |
ND |
|
|
||
|
The percentage of responders was calculated as described in the Methods section. Serum samples were tested at a dilution of 1:100. The cut-off values for each recombinant protein were: VIR-A4, 0.166; VIR-B10, 0.121; VIR-C1, 0.119; VIR-C2, 0.136; VIR-C16, 0.183; VIR-E5, 0.116; VIR-E8, 0.251; AMA-1, 0.341; MSP119, 0.192 (for IgG). VIR-A4, 0.165; VIR-B10, 0.099; VIR-C1, 0.204; VIR-C2, 0.190; VIR-C16, 0.138; VIR-E5, 0.143; VIR-E8, 0.150 (for IgM) |
||
|
Oliveira et al. Malaria Journal 2006 5:83 doi:10.1186/1475-2875-5-83 |
||
